Research Topics
Species | Deepak L BhattSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effect of platelet inhibition with cangrelor during PCI on ischemic eventsDeepak L Bhatt
VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02132, USA
N Engl J Med 368:1303-13. 2013..Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects...- Intravenous platelet blockade with cangrelor during PCIDeepak L Bhatt
VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
N Engl J Med 361:2330-41. 2009..Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI)... - Clopidogrel with or without omeprazole in coronary artery diseaseDeepak L Bhatt
Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
N Engl J Med 363:1909-17. 2010..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel... - Acute coronary syndrome update for hospitalistsDeepak L Bhatt
Cardiology, VA Boston Healthcare System, Boston, Massachusetts, USA
J Hosp Med 5:S15-21. 2010..Understanding and implementing the recommendations in these evidence-based guidelines are important parts of hospitalists' practice... - Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosisDeepak L Bhatt
VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02132, USA
JAMA 304:1350-7. 2010..Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear... - Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventionsDeepak L Bhatt
Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Cleve Clin J Med 77:101-9. 2010..Recent studies have helped clarify treatment strategies. Drug-eluting stents have reduced the problem of restenosis, but questions remain about the length of time patients need dual antiplatelet therapy... - Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkitChristopher P Cannon
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Crit Pathw Cardiol 7:223-31. 2008..The updated STEMI tools are available to clinicians online on the STRIVE Website... - Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD programMichelle L O'Donoghue
Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
J Thromb Thrombolysis 34:36-43. 2012..Although atopaxar increased the concentration of Lp-PLA(2) and IL-18, the clinical relevance of these findings remains unknown and warrants further investigation and validation... - Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue
Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 123:1843-53. 2011..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS... - Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH RegistryAmit Kumar
Department of Hospital Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Crit Pathw Cardiol 8:104-11. 2009..Few data are available for outpatients in actual clinical practice, especially those without known heart disease treated by physicians trained in different specialties across the geographic regions of the United States... - Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)Christopher P Cannon
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 105:445-52. 2010..In conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin for secondary prevention, and 15% are not treated with any antithrombotic agent... 
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyDeepak L Bhatt
VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, 1400 VFW Parkway, Boston, MA 02132, USA
Eur Heart J 33:2143-50. 2012..We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events...- Predictors of adherence to performance measures in patients with acute myocardial infarctionDharam J Kumbhani
Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am J Med 126:74.e1-9. 2013..To understand how such gaps in recommended care may be narrowed further, it may be useful to determine those factors associated with lessened adherence to guideline-based care... - Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelinesPei Hsiu Huang
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Clin Cardiol 35:396-403. 2012..Using data from GWTG, we examined trends associated with the smoking-cessation counseling (SCC) performance measure... - Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromesDeepak L Bhatt
VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA, USA
Eur Heart J 30:1195-202. 2009.... - Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet fAndrew L Frelinger
Center for Platelet Research Studies, Division of Hematology Oncology, Boston Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
J Am Coll Cardiol 61:872-9. 2013..This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics... - Clinical trials update from the annual scientific session of the American College of Cardiology 2006Christopher P Cannon
Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Cardiol 98:36Q-41Q. 2006 - Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summaryDavid P Faxon
Brigham and Women s Hospital, 1620 Tremont St, Boston, MA 02120, USA
Circ Cardiovasc Interv 4:522-34. 2011.... - Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkitChristopher P Cannon
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Crit Pathw Cardiol 7:43-81. 2008..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS... - The state of periprocedural antiplatelet therapy after recent trialsNihar R Desai
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
JACC Cardiovasc Interv 3:571-83. 2010.... - Rivaroxaban in patients with a recent acute coronary syndromeJessica L Mega
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 366:9-19. 2012..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome... - Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease programSamip Vasaiwala
Division of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts, USA
Clin Cardiol 35:541-7. 2012..We studied the impact of chronic renal insufficiency on mortality and quality of inpatient care for AMI from the American Heart Association's Get With The Guidelines-Coronary Artery Disease Program... - Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)Hector M Medina
Cardiac MR, PET, CT Program, Department of Radiology, Division of Cardiology, Massachusetts General Hospital, Boston, USA
Am Heart J 162:283-290.e2. 2011..To determine the adherence to national guidelines and in-hospital mortality of older patients with acute myocardial infarction (AMI) using a national database... - Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitusJacob A Udell
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Clin Cardiol 35:722-9. 2012..In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus... - A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteersAndrew L Frelinger
Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Am Coll Cardiol 59:1304-11. 2012..The aim of this study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel... - Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspectiveDavid P Faxon
Division of Cardiology, Brigham and Women s Hospital, 1620 Tremont Street, OBC 3 12J, Boston, MA 02120, USA
Thromb Haemost 106:572-84. 2011.... - Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trialsSripal Bangalore
New York University School of Medicine, New York, USA
Arch Neurol 68:172-84. 2011..The role of carotid artery stenting (CAS) when compared with carotid endarterectomy (CEA) is controversial, with recent trials showing an increased risk of harm with CAS... - Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg
Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 99:1212-5. 2007..In conclusion, use of evidence-based, guideline-recommended therapies in outpatients with CAD needs to improve, especially in medically managed patients... - Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attackJeremiah P Depta
VA Boston Healthcare System, 1400 VFW Parkway, Boston, MA 02132, USA
Stroke 43:2376-81. 2012..We studied the clinical outcomes associated with platelet function-guided modifications in antiplatelet therapy in patients with ischemic stroke or transient ischemic attack... - Role of antiplatelet therapy across the spectrum of patients with coronary artery diseaseDeepak L Bhatt
Veterans Affairs Boston Healthcare System, and Brigham and Women s Hospital, Boston, Massachusetts, USA
Am J Cardiol 103:11A-19A. 2009.... - Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease TrialStephen D Wiviott
Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Circulation 123:1854-63. 2011..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD... - Contemporary management of peripheral arterial disease: III. Endovascular and surgical managementAmjad Almahameed
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
Cleve Clin J Med 73:S45-51. 2006.... - Antiplatelet therapy in coronary heart disease preventionKumaran Kolandaivelu
Division of Cardiology, Brigham and Women s Hospital, Boston, MA 02115, USA
Cardiol Clin 29:71-85. 2011..This review provides a current appraisal of antiplatelet drug use in CHD prevention and discusses key barriers to achieving its full potential in real-world practice... - The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 studyBenjamin M Scirica
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Am Heart J 162:818-825.e6. 2011.... - Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherenceKumaran Kolandaivelu
Veterans Affairs Boston Healthcare System, Brigham and Women s Hospital and Harvard Medical School, 1400 VFW Parkway, Boston, MA 02132, USA
Nat Rev Cardiol 7:461-7. 2010.... - Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantationPei Hsiu Huang
From the Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School and the Department of Medicine, Cardiovascular Division, VA Boston Healthcare System, Boston, MA
Crit Pathw Cardiol 11:177-85. 2012.... - Antiplatelet therapy and proton pump inhibition: cause for concern?Jeremiah P Depta
Division of Cardiology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
Curr Opin Cardiol 27:642-50. 2012..To review the current evidence on the clinical significance of the drug-drug interactions between the available antiplatelet agents and proton pump inhibitors (PPIs)... - Increasing proportion of clinical trials using noninferiority end pointsVenkatesh L Murthy
Division of Cardiovascular Medicine, Department of Internal Medicine, Cardiovascular Imaging Program, and TIMI Study Group, Brigham and Women s Hospital, and VA Boston Healthcare System, Boston, Massachusetts
Clin Cardiol 35:522-3. 2012..Drs. Murthy and Desai have received consulting fees from Novo Nordisk. The authors have no other funding, financial relationships, or conflicts of interest to disclose... - Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertensionBradley A Maron
Department of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury, MA, USA
Crit Pathw Cardiol 11:40-2. 2012..The current work aims to bridge this gap by providing a stepwise procedure for the safe administration of clinically indicated intravenous epoprostenol during pulmonary vasoreactivity testing... - Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillatorRahul Sakhuja
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
Am J Cardiol 103:735-41. 2009..7-fold increased mortality risk in patients who receive dialysis compared with those who do not. Beta blockers may be less cardioprotective in patients with ICDs who are on dialysis... - Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)Michael R Tamberella
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
Am J Cardiol 89:1429-31. 2002